SCHEMBL19620573

SCHEMBL19620573

NC1=C(OSCc2ccccn2)C(=O)C(c2ccc(Cl)cc2)O1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
NPC1 O15118 3/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35
ALDH1A1 P00352 1/20 0.34
PDE10A Q9Y233 1/20 0.34
METAP2 P50579 1/20 0.33
PNP P00491 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
LMNA P02545 2/20 0.32
TP53 P04637 1/20 0.32
DAO P14920 1/20 0.32
CNR1 P21554 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19620522 0.83 KDM4E (0.42) RAB9AMAPTKDM4EPOLBALDH1A1
SCHEMBL19620490 0.83 ADK (0.38) RAB9ASMN1; SMN2NPC1MAPTKDM4E
SCHEMBL19620342 0.82 MDM2 (0.36) RAB9AMAPTKDM4EPOLBALDH1A1
SCHEMBL19620540 0.81 MAPT (0.37) RAB9ASMN1; SMN2MAPTKDM4EPOLB
SCHEMBL19620643 0.80 RAB9A (0.36) RAB9ASMN1; SMN2NPC1MAPTKDM4E
SCHEMBL16931689 0.80 RAB9A (0.35) RAB9ASMN1; SMN2NPC1MAPTKDM4E
SCHEMBL19620576 0.79 MAPT (0.36) RAB9AMAPTKDM4EPOLBALDH1A1
SCHEMBL19620551 0.79 ALDH1A1 (0.36) RAB9ANPC1MAPTKDM4EPOLB
SCHEMBL19620524 0.79 POLB (0.38) RAB9ASMN1; SMN2MAPTKDM4EPOLB
SCHEMBL19620511 0.79 MAPT (0.35) RAB9ASMN1; SMN2NPC1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3345596-A2 INHIBITORS OF BETA-HYDROLASE FOR TREATMENT OF CANCER RHODE ISLAND HOSPITAL (US) 2018-07-11 EP disclosed
EP-2897607-B1 INHIBITORS OF BETA-HYDROLASE FOR TREATMENT OF CANCER RHODE ISLAND HOSPITAL (US) 2017-11-22 EP disclosed